Omicron variant 263
Vol. 63(3): 262 - 274, 2022
Sub-linajes de la variante Ómicron del SARS-CoV-2: mutaciones
características y su relación con el comportamiento
epidemiológico.
Invest Clin 2022; 63 (3): 262 – 274
Palabras clave: COVID-19; SARS-CoV-2; variante de preocupación Ómicron;
mutaciones; tropismo.
Resumen. A finales de 2021 surge la variante Omicron del SARS-CoV-2, el
coronavirus responsable de la COVID-19, causando preocupación inmediata,
debido al aumento explosivo de casos en Suráfrica, y a su gran cantidad de
mutaciones. Este estudio describe las mutaciones características de la variante
Ómicron en la proteína de la Espiga (S) y el comportamiento de las sucesivas
olas epidémicas asociadas a la circulación de sus sub-linajes en todo el mundo.
Las mutaciones en la proteína S descritas están relacionadas con su capacidad
para evadir la protección provocada por las vacunas actuales, así como su posi-
ble susceptibilidad reducida a las proteasas del hospedero para la preparación
del proceso de fusión. Se infiere cómo esto podría estar relacionado con su
cambio en el tropismo, con una replicación mayor en las células epiteliales
nasales y menor en el tejido pulmonar, rasgos probablemente asociados a su
aparente menor gravedad en comparación con otras variantes.
Received: 10-07-2022 Accepted: 22-07-2022
INTRODUCTION
SARS-CoV-2 infection, responsible for
the COVID-19 pandemic, has caused more
than 550 million cases and more than 6
million deaths worldwide until June 2022.
This virus belongs to the family Coronaviri-
dae. This family comprises enveloped virus-
es, with a positive sense genome of around
30,000 nt. In the case of SARS-CoV-2, the
genome codes for four structural proteins
(nucleocapsid or N, spike or S, membrane
or M and envelope or E), 15 non-structural
proteins and eight accessory proteins. The S
protein contains two regions: S1, which in-
cludes the receptor-binding domain (RBD),
and S2, with the furin-cleavage site and the
fusion peptide. RBD, specifically the receptor
binding motif (RBM), is the region respon-
sible for the attachment to the angiotensin-
converting enzyme 2 (ACE2) cellular recep-
tor (Fig. 1)1,2. Two other putative receptors
(Asialoglycoprotein Receptor 1 - ASGR1- and
KREMEN1) have been described recently for
SARS-CoV-2, which are not used by the previ-
ous SARS-CoV. The virus appears to interact
with these two additional receptors through
the RBD and also with N-terminal domain of
the S1 region3,4. These new candidates add
to the list of other potential ligands that
may interact with SARS-CoV-25,6.
During these two years of a high rate
of replication, this virus has accumulated
several mutations, allowing for its clas-
sification in more than 2000 lineages by
June 20227-9. Some of these lineages were
denominated as variants by WHO10. These
variants (lineages of viruses sharing partic-
ular types of mutations) emerged since the
end of 2020, and were defined as Variants
Under Monitoring (VUM), Variants of Inter-
est (VOI), and Variants of Concern (VOC),